Statins for Treatment of Chronic Liver Disease

Overview

Journal Curr Opin Gastroenterol

Specialty Gastroenterology

Date 2021 Mar 3

PMID 33654016

Citations 5

Authors

Mohamad Kareem Marrache

Don C Rockey

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Statins are a class of lipid lower medications used primarily in patients with high-risk cardiovascular disease. Since their development, statins have been considered to be harmful in patients with liver disease, and many of the prescribing information labels consider them to be contraindicated in patients with active liver disease. However, recent studies have shown the contrary, warranting further investigation and discussion. This review aims to describe the latest literature on the mechanism, safety profile and potential benefits of statins use on the natural history of chronic liver disease (CLD) progression and its complications.

Recent Findings: A number of recently published studies have added to the existing body of literature supporting the concept that statins are safe and likely to be beneficial for treating patients with CLD. Patients with CLD including hepatitis B virus infection, hepatitis C virus infection, nonalcoholic fatty liver disease and alcohol on statins have been shown to have a lower rate of decompensating events, lower incidence of hepatocellular cancer, a lower rate of infections, and increased survival. However, the majority of the available literature supporting statin use in patients with liver disease comes from retrospective observational studies with high potential for bias.

Summary: Statins appear to be safe in patients with compensated cirrhosis, and evidence suggests that they may reduce fibrosis, even in patients with advanced fibrosis and cirrhosis. Further high-quality research on this topic is needed to fully delineate the effect of statins in patients with liver disease.

Citing Articles

Nrf2/HO-1, NF-κB and PI3K/Akt signalling pathways decipher the therapeutic mechanism of pitavastatin in early phase liver fibrosis in rats.

Elbaset M, Mohamed B, Hessin A, Abd El-Rahman S, Esatbeyoglu T, Afifi S J Cell Mol Med. 2024; 28(3):e18116.

PMID: 38214394 PMC: 10844702. DOI: 10.1111/jcmm.18116.

Low-dose atorvastatin therapy induced rhabdomyolysis in a liver cirrhosis patient - a case report.

Bhattarai S, Pradhan S, Bhattarai S Ann Med Surg (Lond). 2023; 85(10):5232-5234.

PMID: 37811121 PMC: 10553173. DOI: 10.1097/MS9.0000000000001231.

Hepatic macrophage mediated immune response in liver steatosis driven carcinogenesis.

Tu T, Alba M, Datta A, Hong H, Hua B, Jia Y Front Oncol. 2022; 12:958696.

PMID: 36276076 PMC: 9581256. DOI: 10.3389/fonc.2022.958696.

Advancements in MAFLD Modeling with Human Cell and Organoid Models.

Wang S, Yan J, Chan Y Int J Mol Sci. 2022; 23(19).

PMID: 36233151 PMC: 9569457. DOI: 10.3390/ijms231911850.

Simvastatin ameliorates oxidative stress levels in HepG2 cells and hyperlipidemic rats.

Verma K, Makwana S, Paliwal S, Paliwal V, Jain S, Paliwal S Curr Res Pharmacol Drug Discov. 2022; 3:100088.

PMID: 35146420 PMC: 8818901. DOI: 10.1016/j.crphar.2022.100088.

References

Kamal S, Khan M, Seth A, Cholankeril G, Gupta D, Singh U . Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2017; 112(10):1495-1505. DOI: 10.1038/ajg.2017.170. View

Kamm C, El-Koussy M, Humpert S, Findling O, von Bredow F, Burren Y . Atorvastatin added to interferon β for relapsing multiple sclerosis: a randomized controlled trial. J Neurol. 2012; 259(11):2401-13. PMC: 3484273. DOI: 10.1007/s00415-012-6513-7. View

Kamm C, El-Koussy M, Humpert S, Findling O, Burren Y, Schwegler G . Atorvastatin added to interferon beta for relapsing multiple sclerosis: 12-month treatment extension of the randomized multicenter SWABIMS trial. PLoS One. 2014; 9(1):e86663. PMC: 3907426. DOI: 10.1371/journal.pone.0086663. View

Abraldes J, Villanueva C, Aracil C, Turnes J, Hernandez-Guerra M, Genesca J . Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. Gastroenterology. 2016; 150(5):1160-1170.e3. DOI: 10.1053/j.gastro.2016.01.004. View

Bloom S, Kemp W, Lubel J . Portal hypertension: pathophysiology, diagnosis and management. Intern Med J. 2014; 45(1):16-26. DOI: 10.1111/imj.12590. View

Russo M, Hoofnagle J, Gu J, Fontana R, Barnhart H, Kleiner D . Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology. 2014; 60(2):679-86. PMC: 4110177. DOI: 10.1002/hep.27157. View

Lahera V, Goicoechea M, de Vinuesa S, Miana M, de Las Heras N, Cachofeiro V . Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins. Curr Med Chem. 2007; 14(2):243-8. DOI: 10.2174/092986707779313381. View

Dickerman B, Garcia-Albeniz X, Logan R, Denaxas S, Hernan M . Avoidable flaws in observational analyses: an application to statins and cancer. Nat Med. 2019; 25(10):1601-1606. PMC: 7076561. DOI: 10.1038/s41591-019-0597-x. View

Bishnu S, Ahammed S, Sarkar A, Hembram J, Chatterjee S, Das K . Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study. Eur J Gastroenterol Hepatol. 2017; 30(1):54-59. DOI: 10.1097/MEG.0000000000001006. View

10.

Marrone G, Maeso-Diaz R, Garcia-Cardena G, Abraldes J, Garcia-Pagan J, Bosch J . KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. Gut. 2014; 64(9):1434-43. DOI: 10.1136/gutjnl-2014-308338. View

11.

Mellinger J, Richardson C, Mathur A, Volk M . Variation among United States hospitals in inpatient mortality for cirrhosis. Clin Gastroenterol Hepatol. 2014; 13(3):577-84. PMC: 4333025. DOI: 10.1016/j.cgh.2014.09.038. View

12.

Sano M, Bell K, Galasko D, Galvin J, Thomas R, van Dyck C . A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology. 2011; 77(6):556-63. PMC: 3149154. DOI: 10.1212/WNL.0b013e318228bf11. View

13.

Emberson J, Kearney P, Blackwell L, Newman C, Reith C, Bhala N . Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One. 2012; 7(1):e29849. PMC: 3261846. DOI: 10.1371/journal.pone.0029849. View

14.

Malizia G, DAmico G . Statins in Cirrhosis: The Magic Pill?. Hepatology. 2016; 63(6):2047-9. DOI: 10.1002/hep.28616. View

15.

Huang Y, Lee C, Yang S, Fu S, Chen Y, Wang T . Statins Reduce the Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients: A Nationwide Cohort Study. Am J Gastroenterol. 2016; 111(7):976-85. DOI: 10.1038/ajg.2016.179. View

16.

Bjornsson E . Hepatotoxicity of statins and other lipid-lowering agents. Liver Int. 2016; 37(2):173-178. DOI: 10.1111/liv.13308. View

17.

Liu S, Premont R, Kontos C, Zhu S, Rockey D . A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension. Nat Med. 2005; 11(9):952-8. DOI: 10.1038/nm1289. View

18.

Matsushita Y, Sugihara M, Kaburagi J, Ozawa M, Iwashita M, Yoshida S . Pravastatin use and cancer risk: a meta-analysis of individual patient data from long-term prospective controlled trials in Japan. Pharmacoepidemiol Drug Saf. 2009; 19(2):196-202. DOI: 10.1002/pds.1870. View

19.

Abraldes J, Rodriguez-Vilarrupla A, Graupera M, Zafra C, Garcia-Caldero H, Garcia-Pagan J . Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. J Hepatol. 2007; 46(6):1040-6. DOI: 10.1016/j.jhep.2007.01.020. View

20.

Simon T, Duberg A, Aleman S, Hagstrom H, Nguyen L, Khalili H . Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population. Ann Intern Med. 2019; 171(5):318-327. PMC: 8246628. DOI: 10.7326/M18-2753. View